Click Therapeutics Announces Multiple Publications of Clinical Data Supporting Digital Therapeutics™ Programs for Smoking Cessation and Major Depressive Disorder

  • Efficacy results of Click’s patent-pending cognitive-emotional digital therapeutic for major depressive disorder to be presented at the Society of Biological Psychiatry Annual Scientific Convention in San Diego, CA on May 19, 2017.
  • Results of a 416-person clinical trial of Clickotine® for smoking cessation published in JMIR mHealth and uHealth on April 25, 2017.
  • Long-term follow-up results of Clickotine trial presented at the Annual Meeting of the Society for Research on Nicotine and Tobacco in Florence, Italy, on March 11, 2017.
  • Clinical data on associations between depression and anxiety symptoms and smoking cessation in the Clickotine trial to be presented at the Association for Psychological Science Annual Convention in Boston, MA on May 27, 2017.

NEW YORK--()--Click Therapeutics, Inc. (“Click”), a company developing a suite of personalized data-driven digital therapeutics for chronic health conditions, announces today multiple publications of research data supporting its digital therapeutics for smoking cessation and major depressive disorder.

Interim efficacy results of Click’s novel cognitive-emotional digital therapeutic for major depressive disorder will be presented at the Society of Biological Psychiatry Annual Scientific Convention on May 19, 2017, in San Diego, CA. Results show that compared to an active control group, Click’s intervention resulted in significantly greater MDD symptom reduction after the 6-week regimen (42.9% compared to 15.7% in the control group).

The results of a 416-person clinical trial of Clickotine, a digital therapeutic for smoking cessation, have been published in JMIR mHealth and uHealth. This trial found Clickotine to be engaging for users (100.6 app opens on average), as well as efficacious (45% of users in the ITT sample reported achieving abstinence from smoking for at least 7 days at the end of the 8-week trial; 26.2% reported achieving at least 30-day abstinence). Indicators suggested that remaining active with the program was associated with smoking cessation.

Long-term efficacy results of the Clickotine trial were presented at the Annual Meeting of the Society for Research on Nicotine and Tobacco in Florence, Italy, on March 11. At 6-months post-enrollment, 35.3% of users in the ITT sample reported achieving 30-day abstinence from smoking, an increase from 26.2% of users reporting abstinence at the end of the 8-weeks trial.

Clinical data on associations between depression and anxiety symptoms and smoking cessation in the Clickotine trial will be presented at the Association for Psychological Science Annual Convention on May 27, 2017, in Boston, MA. Whereas baseline depression and anxiety symptoms were not predictive of smoking cessation at the end of the Clickotine trial, the degree of depression or anxiety symptoms experienced at study outcome was significantly correlated with cessation such that greater degree of symptoms was associated with less likelihood of quitting. Moreover, baseline confidence in ability to quit predicted smoking cessation at the end of the trial.

According to Brian Iacoviello, PhD, Director of Scientific Affairs at Click Therapeutics, "These publications demonstrate the robust foundation in science and rigorous research for everything that Click develops. Ongoing and future studies are poised to yield even more data and publications on Click's developed products. We are excited to share the science of digital therapeutics with the research community, and to reach the patients who stand to benefit."

David Benshoof Klein, CEO of Click Therapeutics, remarks: “these publications of our clinical data are not only very encouraging for the products that they support, but also for the versatility of Click’s platform. Click has demonstrated an ability to develop digital therapeutics that are engaging and efficacious for a variety of indications, and that are supported by rigorous clinical research.”

Copies of the above referenced publications can be viewed at the Society of Biological Psychiatry website at SOBP.org, via JMIR mHealth and uHealth at mhealth.jmir.org/2017/4/e56, the Society for Research on Nicotine and Tobacco website at SRNT.org, and the Association for Psychological Science website at PsychologicalScience.org. Following each publication, the data presented will be available on the Publications page of the Company's website at ClickTherapeutics.com.

About Click Therapeutics

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavioral modification. Click Therapeutics™ digital interventions enable change within individuals, and can be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalized user experience to drive cognitive and behavioral outcomes. As the leader in Digital Therapeutics solutions, Click Therapeutics is building the brains behind digital health. For more information, visit ClickTherapeutics.com.

Contacts

Click Therapeutics, Inc.
Media:
Sarah Jackson, 646-844-2158
sarah@clicktherapeutics.com
or
Investors:
Ted Silver, 646-844-2158
ted@clicktherapeutics.com

Release Summary

Click Therapeutics Announces Multiple Publications of Clinical Data Supporting Digital Therapeutics™ Programs for Smoking Cessation and Major Depressive Disorder

Contacts

Click Therapeutics, Inc.
Media:
Sarah Jackson, 646-844-2158
sarah@clicktherapeutics.com
or
Investors:
Ted Silver, 646-844-2158
ted@clicktherapeutics.com